Preventing Smoking Relapse After Total Joint Replacement Surgery

NCT ID: NCT03673228

Last Updated: 2021-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-15

Study Completion Date

2021-01-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hospitalization for elective knee or hip replacement surgery presents an outstanding opportunity to motivate people to quit smoking, because it provides an opportunity to encourage patients to remain smoke-free as they proactively quit to optimize their surgery outcomes. This study will conduct a comparative effectiveness trial of patients who quit smoking pre-operatively, comparing the current standard of care with a novel comprehensive relapse prevention intervention guided by Marlatt's Relapse Prevention Model.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The specific aims of this study are to evaluate the effectiveness and cost-effectiveness of the relapse prevention intervention and will: 1) compare the effectiveness of standard post-operative cessation treatment with a comprehensive relapse prevention intervention on smoking cessation outcomes; 2) conduct a comparative economic analysis to assess the value of the relapse prevention intervention for patients and the healthcare system; and 3) explore the impact of the interventions on surgical complications and readmissions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Smoking Smoking Cessation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Group

Participants randomized to the Intervention Arm will receive counseling that includes:

* A Visit prior to discharge
* Follow up calls after discharge
* Text Messaging Support
* Caregiver Support

Group Type EXPERIMENTAL

Comprehensive Relapse Prevention Intervention

Intervention Type BEHAVIORAL

This intervention consists of 4 components:

1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling
2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit
3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit
4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations

Nicotine Replacement Therapy (NRT)

Intervention Type DRUG

Patients in both arms will be encouraged to receive NRT

Standard treatment

Patients will receive current usual care.

Group Type ACTIVE_COMPARATOR

Standard Treatment Counseling

Intervention Type BEHAVIORAL

Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge

Nicotine Replacement Therapy (NRT)

Intervention Type DRUG

Patients in both arms will be encouraged to receive NRT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Comprehensive Relapse Prevention Intervention

This intervention consists of 4 components:

1. Visit Prior to Discharge: counselor from research team will visit patient at hospital bedside to provide counseling
2. Follow up calls after discharge: 6 proactive counseling calls and initiate unlimited reactive calls to their counselor, at days 1,3,7,14,30,an 60 days after hospital visit
3. Text messaging support: patients will be registered in NCI's Smokefree TXT while in the hospital and will receive multiple daily messages, designed for someone who has already quit
4. Caregiver support: 10 minute training session to the caregiver on how to help patient prevent relapse by increasing self efficacy, maintaining motivation and dealing with high risk situations

Intervention Type BEHAVIORAL

Standard Treatment Counseling

Participants will receive two 10 minute counseling calls from the staff of the preoperative counseling program during the first month after the hospital discharge

Intervention Type BEHAVIORAL

Nicotine Replacement Therapy (NRT)

Patients in both arms will be encouraged to receive NRT

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patient Participants

* Received preoperative smoking cessation counseling through Orthopedic Surgery Quit Smoking Program
* Undergoing elective knee or hip arthroplasty surgery
* Have not smoked any cigarettes in the week prior to admission and carbon monoxide 4 ppm46,47
* Have a cell phone (for text messaging)
* Provide informed consent in English

Caregiver participants:

* Age ≥ 18 years
* Be a caregiver of the patient participant
* Provide informed consent in English

Exclusion Criteria

* Patients will be excluded if they used smokeless tobacco or an electronic cigarette in the last 30 days.
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NYU Langone Health

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Scott Sherman, MD

Role: PRINCIPAL_INVESTIGATOR

NYU Langone Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York University School of Medicine

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18-00723

Identifier Type: -

Identifier Source: org_study_id